Covidien Solitaire: Registry Payments to Hospitals for Each Medical Device Use

Whistleblower Justice Network

Covidien LP agreed to pay $13 million in the Covidien Solitaire registry settlement to resolve allegations that it paid kickbacks to hospitals and institutions to increase medical device sales. The government alleged that a registry paid facilities for using the stroke-treatment medical device and submitting clinical data, while Covidien recruited participants to switch suppliers or keep buying its products. Someone inside sales or clinical research could see both the data being collected and the business the registry was meant to bring in.

The Justice Department announced the civil resolution on December 4, 2018. A former Covidien employee brought the False Claims Act case. The United States alleged that the company’s payments induced Solitaire use and caused false claims to Medicare and Medicaid.

What the Solitaire Registry Paid For

According to the government, the registry paid a participating hospital or institution a fee each time it used a new Solitaire medical device and reported specified clinical data to Covidien. The government described an arrangement lasting about two years beginning in August 2014.

Solitaire is a mechanical thrombectomy medical device intended to restore blood flow and retrieve a blood clot in certain stroke patients. The government alleged that, after receiving Food and Drug Administration clearance for the medical device, Covidien launched the registry to collect information about users’ experiences. Participants reported clinical data about their practices for treating stroke patients.

In the government’s account, the payment trigger connected the research to an actual product use: a hospital used a new Solitaire, supplied the clinical information and received the fee. The institution treating the patient was also the institution being paid by the manufacturer.

The government alleged that Covidien paid hospitals and institutions to induce Solitaire use and caused false claims to Medicare and Medicaid.

The Sales Purpose Behind the Registry

The United States alleged that Covidien selected some hospitals and institutions for the registry to convert their business from a competitor’s product or persuade them to continue using Covidien products. It alleged that Covidien knowingly used the registry to increase sales.

Covidien allegedly paid the customer whose business it wanted to win or keep. The registry supplied a research purpose for the payment. The recruitment allegation supplied the sales purpose. The U.S. Attorney described the fees as a subsidy to facilities that agreed to use Solitaire, often instead of a competitor’s medical device. That put taxpayer-funded treatment behind a product choice the manufacturer allegedly paid to secure.

The 2020 Journal of Forensic and Investigative Accounting paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud identifies cash payments and noncash benefits tied to purchases or recommendations of federally funded health care as part of the reach of kickback schemes. The distinction matters across these medical device cases: the alleged benefit could be a registry fee or access to research equipment, and the recipient could be an institution or a physician. We follow that benefit to the medical device choice and the government money paying for treatment.

Earlier Medical Device Registries Raised the Same Sales Question

St. Jude Medical’s 2011 registry settlement and Medtronic’s 2011 studies and registries settlement also concerned alleged payments to induce medical device selection, with physicians as the recipients. In the Solitaire matter, the alleged recipients were hospitals and institutions.

What Evidence Is Needed to Prove Fraud?

For a registry-payment case, the evidence needs to connect the payment arrangement, the reason for recruiting an institution, its medical device use and the resulting government claims. Those are the links in the Solitaire allegations.

We examine registry agreements and payment schedules alongside participation records, medical-device-use information and clinical-data submissions. Those materials can show what event earned the fee and which institution received it. Sales-account communications can address why that institution was recruited and whether switching or retaining business was the objective.

Hospital product-selection records and the Medicare or Medicaid claim history address the next part of the story: what the institution used and what was billed. Reading those records together connects the manufacturer’s commercial decision to the care the government paid for.

Your part of the transaction may explain how the other parts fit. Someone handling clinical-data submissions may know when a fee became payable; someone handling the sales account may know why that hospital was invited. Our whistleblower experts work with you to connect that knowledge to the healthcare fraud allegation.

How Much Is a Whistleblower Claim Worth?

The former Covidien employee’s announced award from the Solitaire civil action was about $2 million. The employee had worked for Covidien from 2012 to 2014 and brought the case under the False Claims Act’s qui tam provisions.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Saw What the Registry Was Buying

If your work connected registry fees with hospital accounts or medical device use, speak to one of our Whistleblower Experts about how the arrangement worked. We build the case with you, bring in medical device fraud whistleblower lawyers who understand research payments and hospital claims, and stay beside you through the pursuit of a recovery.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365